Mumbai,
August 04, 2020: Sun Pharmaceutical Industries Limited.
(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma”
and includes its subsidiaries and/or associate companies) today announced that
it has launched FluGuard® (Favipiravir 200 mg) at an economical price of Rs. 35
per tablet, for the treatment of mild to moderate cases of Covid-19 in India.
Favipiravir is the only oral anti-viral treatment approved in India for the
potential treatment of patients with mild to moderate Covid-19 disease.
Commenting on the launch, Kirti Ganorkar, CEO of India Business, Sun
Pharma said, “With over 50,000
Covid-19 cases being reported daily in India, there is an urgent need to
provide more treatment options to healthcare professionals. We are launching
FluGuard® at an economical price to make the drug accessible to more and more
patients thereby reducing their financial burden. This is in line with our
continuous efforts to support India’s pandemic response.”
The company will work closely with the government and medical community
to ensure availability of FluGuard® to patients across the country. The stocks
of FluGuard® will be available in the market from this week.
FluGuard® is the registered trade mark of Sun Pharma.
Read more: https://bit.ly/39S2jP8
Join for Regular Job Updates in Whats App & Telegram...
Thank You for Visiting
It's a good
ReplyDelete